The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01E | Protein kinase inhibitors | |
4
|
L01EX | Other protein kinase inhibitors | |
5
|
L01EX29 |
| Active Ingredient |
|---|
|
Vimseltinib is a selective small molecule tyrosine kinase inhibitor that targets colony stimulating factor 1 receptor (CSF1R). The CSF1/CSF1R signalling axis has a critical role in the development of tenosynovial giant cell tumour (TGCT). |
| Document | Type | Information Source | |
|---|---|---|---|
| ROMVIMZA Capsule | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| ROMVIMZA Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) |